CytoSorbents Reports Q3 2025 Revenue of $9.5M, Up 10% YoY, and Provides Business Update

Cytosorbents Corp

2025-Q3 EPS reported -$0.04 vs consensus -$0.05 ▲ beat (+16.0%)

Revenue was $9.5 million for Q3 2025, a 10% increase from $8.6 million in Q3 2024, driven by record distributor sales.
Amended credit agreement with Avenue Capital Group added $2.5 million in term loans and extended interest-only period to December 31, 2026.
Workforce reduction of approximately 10% implemented to accelerate path to cash-flow breakeven by Q1 2026, with up to $900,000 in restructuring charges.
Pre-submission meeting request for DrugSorb-ATR De Novo application submitted to FDA; formal submission expected Q1 2026 with regulatory decision anticipated mid-2026.
Gross margin improved to 70% from 61% a year ago; operating loss narrowed to $2.9 million from $4.8 million.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.